FujifilmFujifilm (TSE:4901) has reportedly spent big to double the size of its United Kingdom-based vaccine manufacturing facility.

The Financial Times reported that Fujifilm is spending about $532.8 million (£400 million) to expand its Teesside (north-east England) plant that is making the Novavax COVID-19 vaccine, transforming it with factories specializing in antibody treatments and viral gene therapies.

Get the full story at our sister site, Pharmaceutical Processing World.